A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ONARTUZUMAB (MetMAb) in Combination with Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Standard Chemotherapy for Advanced or Metastatic Disease

Trial Profile

A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ONARTUZUMAB (MetMAb) in Combination with Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Standard Chemotherapy for Advanced or Metastatic Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Erlotinib (Primary) ; Onartuzumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MetLUNG
  • Sponsors Genentech
  • Most Recent Events

    • 22 Dec 2016 Results published in the Lancet Oncology
    • 02 Apr 2016 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 09 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015, according to ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top